The measurement of the lactonase activity of paraoxonase-1 in the clinical evaluation of patients with chronic liver impairment

Clinical Biochemistry

Volumn 42, Issue 1-2, 2009, Pages 91-98

  Marsillach, Judit ^a   Aragonès, Gerard ^a   Beltrán, Raul ^a   Caballeria, Joan ^b   Pedro Botet, Juan ^c   Morcillo Suárez, Carlos ^d   Navarro, Arcadi ^d,e   Joven, Jorge ^a   Camps, Jordi ^a  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d UNIVERSITAT POMPEU FABRA   (Spain)

^e INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

Diagnostic accuracy; Lactonase; Liver diseases; Paraoxonase; Reference interval

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; GENOMIC DNA; GLUCONOLACTONASE;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ARTICLE; BLOOD SAMPLING; CAUCASIAN; CHRONIC LIVER DISEASE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS HEPATITIS;

EID: 57649087483     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2008.09.120     Document Type: Article

References (42)

1. Primo-Parmo S.L., Sorenson R.C., Teiber J., and La Du B.N. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics 33 (1996) 498-507
2. Aviram M., and Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage cell formation during atherosclerosis development. Free Radical Biol. Med. 37 (2004) 1304-1316
3. Fortunato G., and Di Taranto M.D. Polymorphisms and the expression of genes encoding enzymes involved in cardiovascular diseases. Clin. Chim. Acta 381 (2007) 21-25
4. Furlong C.E. Genetic variability in the cytochrome P450-paraoxonase 1 (PON1) pathway for detoxication of organophosphorus compounds. J. Biochem. Mol. Toxicol. 21 (2007) 197-205
5. Draganov D.I., Teiber J.F., Speelman A., Osawa Y., Sunahara R., and La Du B.N. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J. Lipid Res. 46 (2005) 1239-1247
6. Bergmeier C., Siekmeier R., and Gross W. Distribution spectrum of paraoxonase activity in HDL fractions. Clin. Chem. 50 (2004) 2309-2315
7. Khersonsky O., and Tawfik D. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 44 (2005) 6371-6382
8. Mackness M.I., Arrol S., and Durrington P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 286 (1991) 152-154
9. Mackness M.I., Arrol S., and Durrington P.N. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis 104 (1993) 129-135
10. Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Faull K.F., Fogelman A.M., et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 96 (1995) 2882-2891
11. Mackness M.I., and Durrington P.N. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 115 (1995) 243-253
12. Mackness M., and Mackness B. Paraoxonase 1 and atherosclerosis: is the gene or the protein more important?. Free Radical Biol. Med. 37 (2004) 1317-1323
13. Mackness B., Quarck R., Verreth W., Mackness M., and Holvoet P. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome. Arterioscler., Thromb., Vasc. Biol. 26 (2006) 1545-1550
14. Marsillach J., Parra S., Ferré N., Coll B., Alonso-Villaverde C., Joven J., et al. Paraoxonase-1 in chronic liver diseases, neurological diseases, and HIV infection. In: Mackness B., Mackness M., Aviram M., and Paragh G. (Eds). The Paraoxonases: Their Role in Disease Development and Xenobiotic Metabolism (2008), Springer, Dordrecht 187-198
15. Leviev I., Negro F., and James R.W. Two alleles of the human paraoxonase gene produce different amounts of mRNA. Arterioscler., Thromb., Vasc. Biol. 17 (1997) 2935-2939
16. Rodrigo L., Gil F., Hernández A.F., Marina A., Vázquez J., and Pla A. Purification and characterization of paraoxon hydrolase from rat liver. Biochem. J. 321 (1997) 595-601
17. Reuben A. Alcohol and the liver. Curr. Opin. Gastroenterol. 23 (2007) 283-291
18. De Minicis S., and Brenner D.A. NOX in liver fibrosis. Arch. Biochem. Biophys. 462 (2007) 266-272
19. Ferré N., Camps J., Prats E., Vilella E., Paul A., Figuera L., et al. Serum paraoxonase activity: a new additional test for the improved evaluation of chronic liver damage. Clin. Chem. 48 (2002) 261-268
20. Ferré N., Marsillach J., Camps J., Rull A., Coll B., Tous M., et al. Genetic association of paraoxonase-1 polymorphisms and chronic hepatitis C virus infection. Clin. Chim. Acta 361 (2005) 205-210
21. Marsillach J., Ferré N., Vila M.C., Lligoña A., Mackness B., Mackness M., et al. Serum paraoxonase-1 in chronic alcoholics: relationship with liver disease. Clin. Biochem. 40 (2007) 645-650
22. Gaidukov L., and Tawfik D. The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity. J. Lipid Res. 48 (2007) 1637-1646
23. Bertran N., Camps J., Fernández-Ballart J., Arija V., Ferre N., Tous M., et al. Diet and lifestyle are associated with serum C-reactive protein concentrations in a population-based study. J. Lab. Clin. Med. 145 (2005) 41-46
24. Barrett J.C., Fry B., Maller J., and Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21 (2005) 263-265
25. Zweig M.H., and Campbell G. Receiver-operating characteristics (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin. Chem. 39 (1993) 561-577
26. Bruns D.E., Huth E.J., Magid E., and Young D.S. Toward a checklist for reporting studies of diagnostic accuracy of medical tests. Clin. Chem. 46 (2000) 893-895
27. Bossuyt P.M., Reitsma J.B., Bruns D.E., Gatsonis C.A., Glasziou P.P., Irwing L.M., et al. Towards a complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for reporting of diagnostic accuracy. Clin. Chem. 49 (2003) 1-6
28. Simó J.M., Camps J., Gómez F., Ferré N., and Joven J. Evaluation of a fully-automated particle-enhanced turbidimetric immunoassay for the measurement of plasma lipoprotein(a). Population-based reference values in an area with low incidence of cardiovascular disease. Clin. Biochem. 36 (2003) 129-134
29. Simó J.M., Joven J., Clivillé X., and Sans T. Automated latex agglutination immunoassay of serum ferritin with a centrifugal analyzer. Clin. Chem. 40 (1994) 625-629
30. Khersonsky O., and Tawfik D.S. Chromogenic and fluorogenic assays for the lactonase activity of serum paraoxonases. Chem. Biochem. 7 (2006) 49-53
31. Gaidukov L., Rosenblat M., Aviram M., and Tawfik D.S. The 192 R/Q polymorphisms of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux. J. Lipid Res. 47 (2006) 2492-2502
32. Furlong C.E. Paraoxonases: an historical perspective. In: Mackness B., Mackness M., Aviram M., and Paragh G. (Eds). The Paraoxonases: Their Role in Disease Development and Xenobiotic Metabolism (2008), Springer, Dordrecht 3-31
33. Brophy V.H., Hastings M.D., Cledenning J.B., Richter R.J., Jarvik G.P., and Furlong C.E. Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 11 (2001) 77-84
34. Brophy V.H., Jampsa R.L., Cledenning J.B., McKinstry L.A., Jarvik G.P., and Furlong C.E. Effects of 5′regulatory-region polymorphisms of paraoxonase-gene (PON1) expression. Am. J. Hum. Genet. 68 (2001) 1428-1436
35. Rojas-García A.E., Solís-Heredia M.J., Piña-Guzmán B., Vega L., López-Carrillo L., and Qintanilla-Vega B. Genetic polymorphisms and activity of PON1 in a Mexican population. Toxicol. Appl. Pharmacol. 205 (2005) 282-289
36. Holland N., Furlong C., Bastaki M., Richter R., Bradman A., Huen K., et al. Paraoxonase polymorphisms, haplotypes, and enzyme activity in Latino mothers and newborns. Environ. Health Perspect. 114 (2006) 985-991
37. Carlson C.S., Heagerty P.J., Hatsukami T.S., Richter R.J., Ranchalis J., Lewis J., et al. TagSNP analyses of the PON gene cluster: effects on PON1 activity, LDL oxidative susceptibility, and vascular disease. J. Lipid Res. 47 (2006) 1014-1024
38. Saeed M., Perwaiz Iqbal M., Yousouf F.A., Perveen S., Shafiq M., Sajid J., et al. Interactions and associations of paraoxonase gene cluster polymorphisms with myocardial infarction in a Pakistani population. Clin. Genet. 71 (2007) 238-244
39. Sanghera D.K., Aston C.E., Saha N., and Kamboh M.I. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am. J. Hum. Genet. 62 (1998) 36-44
40. Hofer S.E., Bennetts B., Chan A.K., Holloway B., Karschimkus C., Jenkins A.J., et al. Association between PON1 polymorphisms, PON activity and diabetes complications. J. Diab. Complications 20 (2006) 322-328
41. Gressner O.A., Weiskirchen R., and Gressner A.M. Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options. Comp. Hepatol. 6 (2007) 7
42. Gressner O.A., Weiskirchen R., and Gressner A.M. Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin. Chim. Acta 381 (2007) 107-113